Dr. Ronald Witteles, an Advanced Heart Failure and Transplant Cardiologist at Stanford, dives into the promising Nex-Z trial investigating a CRISPR-Cas9 treatment for ATTR cardiac amyloidosis. Listeners will learn how this innovative gene-editing technology shows potential for effective therapies targeting protein misfolding. Witteles discusses the trial's safety results, significant TTR level reductions, and anticipates future applications, shedding light on the evolution of heart failure treatments and the hope for one-time therapies.